Imprimis Pharmaceuticals Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Imprimis Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Imprimis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Imprimis Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Fifty Two Week Low | 1.71 | |
| Target High Price | 11.50 | |
| Fifty Two Week High | 7.06 | |
| Target Low Price | 10.00 |
Imprimis |
Imprimis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Imprimis Pharmaceuticals on February 5, 2024 and sell it today you would earn a total of 100.00 from holding Imprimis Pharmaceuticals or generate -100.0% return on investment over 90 days. Imprimis Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Imprimis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Imprimis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imprimis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Imprimis Pharmaceuticals, and traders can use it to determine the average amount a Imprimis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMMY |
Based on monthly moving average Imprimis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imprimis Pharmaceuticals by adding Imprimis Pharmaceuticals to a well-diversified portfolio.
Imprimis Pharmaceuticals Fundamentals Growth
Imprimis Stock prices reflect investors' perceptions of the future prospects and financial health of Imprimis Pharmaceuticals, and Imprimis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imprimis Stock performance.
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 | |||
| Profit Margin | (16.81) % | |||
| Operating Margin | (13.94) % | |||
| Current Valuation | 120.54 M | |||
| Shares Outstanding | 23.28 M | |||
| Price To Earning | (2.02) X | |||
| Price To Book | 23.40 X | |||
| Price To Sales | 2.88 X | |||
| Revenue | 37.33 M | |||
| EBITDA | (3.35 M) | |||
| Cash And Equivalents | 6.24 M | |||
| Cash Per Share | 0.27 X | |||
| Total Debt | 15.28 M | |||
| Debt To Equity | 343.10 % | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | 429 K | |||
| Earnings Per Share | (0.30) X | |||
| Total Asset | 14.13 M | |||
| Retained Earnings | (57.76 M) | |||
| Current Asset | 5.87 M | |||
| Current Liabilities | 5.37 M | |||
Things to note about Imprimis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Imprimis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Imprimis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imprimis Pharmaceuticals is not yet fully synchronised with the market data | |
| Imprimis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Imprimis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Imprimis Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 37.33 M. Net Loss for the year was (6.28 M) with profit before overhead, payroll, taxes, and interest of 13.27 M. |
- Analyzing Imprimis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imprimis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Imprimis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imprimis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imprimis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imprimis Pharmaceuticals' stock. These opinions can provide insight into Imprimis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |